Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation (PREPARE II)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03787732 |
Recruitment Status :
Recruiting
First Posted : December 26, 2018
Last Update Posted : December 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acute Respiratory Failure Intubation Complication Hypotension on Induction | Drug: Fluid Bolus Other: No Fluid Bolus | Phase 4 |
The PREPARE II trial is a prospective, parallel group, pragmatic, randomized trial comparing the effect of a preintubation fluid bolus to no preintubation fluid bolus on the incidence of cardiovascular collapse during and after endotracheal intubation in critically ill adults.
Patients admitted to the study units who are deemed by their clinical team to require intubation and fulfill inclusion criteria without meeting exclusion criteria will be randomized 1:1 to receive either an intravenous fluid bolus or no intravenous fluid bolus. All other decisions regarding airway management will remain at the discretion of the treating provider.
Conduct of the trial will be overseen by a Data Safety Monitoring Board. An interim analysis will be performed after the enrollment of 375 patients. The analysis of the trial will be conducted in accordance with a pre-specified statistical analysis plan, which will be submitted for publication or made publicly available prior to the conclusion of enrollment.
The primary outcome is cardiovascular collapse - a composite endpoint defined as one or more of the following:
- Death within 1 hour of intubation
- Cardiac arrest within 1 hour of intubation
- New systolic blood pressure < 65 mmHg between induction and 2 minutes after completion of intubation
- New or increased vasopressor receipt between induction and 2 minutes after completion of intubation
The secondary outcome is 28-day in-hospital mortality
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1065 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation (PREPARE II Trial) |
Actual Study Start Date : | February 1, 2019 |
Estimated Primary Completion Date : | July 1, 2021 |
Estimated Study Completion Date : | October 1, 2021 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Fluid Bolus
For patients randomized to fluid bolus administration, the bedside nurse will obtain 500 mL of a crystalloid solution of the operator's choosing, connect this volume to intravenous infusion tubing, and attach the tubing to any intravenous catheter or intraosseous device. The crystalloid solution will then be placed above the level of the intravenous or intraosseous device and allowed to infuse by gravity or pressure bag. At any time after the initiation of fluid bolus administration, the operator can choose to begin the procedure by administering sedation. Fluid loading will continue until all 500 mL are infused. Fluid infusing prior to the decision to perform endotracheal intubation will not be altered by the current study.
|
Drug: Fluid Bolus
500 milliliters of an intravenous crystalloid solution of the operator's choosing
Other Name: intravenous crystalloid fluid, 500 mL |
Active Comparator: No Fluid Bolus
For patients randomized to no fluid bolus administration, no additional intravenous crystalloid administration will be initiated between randomization and two minutes after completion of endotracheal intubation. Fluid infusing prior to the decision to perform endotracheal intubation will not be affected by the study. Treating clinicians may initiate a fluid bolus at any time for the treatment of cardiovascular collapse (not considered a protocol violation). Treating clinicians may also initiate a fluid bolus at any time if felt to be mandatory for the safe treatment of the patient (if between randomization and two minutes after intubation and in the absence of cardiovascular collapse this will be recorded as a protocol violation).
|
Other: No Fluid Bolus
No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation |
- Cardiovascular collapse [ Time Frame: 1 hour ]
A composite endpoint defined as one or more of the following
- New systolic blood pressure < 65 mmHg between induction and 2 minutes after intubation
- New or increased vasopressor between induction and 2 minutes after intubation
- Cardiac arrest within 1 hour of intubation
- Death within 1 hour of intubation
- 28-day in-hospital mortality [ Time Frame: 28 days ]
- New systolic blood pressure < 65 mmHg between induction and 2 minutes after intubation [ Time Frame: from induction to 2 minutes following tracheal intubation ]
- New or increased vasopressor between induction and 2 minutes after intubation [ Time Frame: from induction to 2 minutes following tracheal intubation ]
- Cardiac arrest within 1 hour of intubation [ Time Frame: 1 hour ]
- Death within 1 hour of intubation [ Time Frame: 1 hour ]
- Lowest systolic blood pressure between induction and 2 minutes after intubation [ Time Frame: from induction to 2 minutes following tracheal intubation ]
- Change in systolic blood pressure from induction to lowest systolic blood pressure [ Time Frame: between induction and 2 minutes following procedure ]
- Ventilator-free days [ Time Frame: 28 days ]
- ICU-free days [ Time Frame: 28 days ]
- Lowest oxygen saturation [ Time Frame: from induction to 2 minutes following tracheal intubation ]Lowest arterial oxygen saturation between induction and 2 minutes after intubation
- Incidence of hypoxemia [ Time Frame: from induction to 2 minutes following tracheal intubation ]Incidence of oxygen saturation < 90% between induction and 2 minutes after intubation
- Incidence of severe hypoxemia [ Time Frame: from induction to 2 minutes following tracheal intubation ]Incidence of oxygen saturation < 80% between induction and 2 minutes after intubation
- Oxygen saturation at 24 hours after intubation [ Time Frame: 24 hours ]
- Fraction of inspired oxygen at 24 hours after intubation [ Time Frame: 24 hours ]
- Positive end expiratory pressure at 24 hours after intubation [ Time Frame: 24 hours ]
- Systolic blood pressure at 24 hours after intubation [ Time Frame: 24 hours ]
- Additional intravenous fluids initiated between induction and 2 minutes after intubation [ Time Frame: from induction to 2 minutes following tracheal intubation ]
- Time from induction to successful intubation [ Time Frame: Duration of procedure (minutes) ]
- Cormack-Lehane grade of glottic view on first attempt [ Time Frame: Duration of procedure (minutes) ]
- Difficulty of intubation [ Time Frame: Duration of procedure (minutes) ]Operator-reported difficulty of intubation on a three-point ordinal scale of: easy, moderate, or difficult.
- Incidence of successful intubation on the first laryngoscopy attempt [ Time Frame: Duration of procedure (minutes) ]
- Number of laryngoscopy attempts [ Time Frame: Duration of procedure (minutes) ]
- Need for additional airway equipment or a second operator [ Time Frame: Duration of procedure (minutes) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient is undergoing endotracheal intubation in a participating unit
- Planned operator is a provider expected to routinely perform endotracheal intubation in the participating unit
- Patient is at least 18 years of age
- Administration of sedation is planned (with or without neuromuscular blockade)
- Positive pressure ventilation between induction and laryngoscopy is planned (e.g., non-invasive ventilation or bag-mask ventilation)
Exclusion Criteria:
- Prisoners
- Pregnant patients
- Urgency of intubation precludes safe performance of study procedures
- Operator feels administration of a fluid bolus is indicated or contraindicated for the safe performance of the procedure

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787732
Contact: Jonathan D Casey, MD | (615) 208-6139 | Jonathan.d.Casey@vumc.org | |
Contact: Matthew W. Semler, MD, MSc | (615) 802-8428 | matthew.w.semler@vumc.org |
United States, Alabama | |
University of Alabama at Birmingham | Recruiting |
Birmingham, Alabama, United States, 35233 | |
Contact: Derek W Russell, MD 205-975-3718 dwrussell@uabmc.edu | |
United States, Louisiana | |
Louisiana State University School of Medicine | Recruiting |
New Orleans, Louisiana, United States, 70112 | |
Contact: David R Janz, MD, MSc 504-568-3167 djanz@lsuhsc.edu | |
Ochsner Medical Center | Ochsner Health System | Recruiting |
New Orleans, Louisiana, United States, 70121 | |
Contact: Kevin M Dischert, MD kevin.dischert@ochsner.org | |
Contact: Derek J Vonderhaar, MD dvonde@lsuhsc.edu | |
United States, Massachusetts | |
Lahey Hospital & Medical Center | Recruiting |
Burlington, Massachusetts, United States, 01805 | |
Contact: James Dargin, MD james.m.dargin@lahey.org | |
Contact: Sue Stempek, PA-C susan.b.stempek@lahey.org | |
United States, Minnesota | |
Hennepin County Medical Center | Recruiting |
Minneapolis, Minnesota, United States, 55415 | |
Contact: Matthew Prekker, M.D., MPH prek0003@umn.edu | |
Contact: Brian Driver Brian.Driver@hcmed.org | |
United States, Mississippi | |
University of Mississippi Medical Center | Recruiting |
Jackson, Mississippi, United States, 39216 | |
Contact: Joseph M Brewer, DO jmbrewer2@umc.edu | |
United States, North Carolina | |
Wake Forest Baptist Medical Center | Recruiting |
Winston-Salem, North Carolina, United States, 27157 | |
Contact: Kevin Gibbs kgibbs@wakehealth.edu | |
United States, Oregon | |
Oregon Health & Science University | Recruiting |
Portland, Oregon, United States, 97239 | |
Contact: Akram Khan, M.D. khana@ohsu.edu | |
United States, Tennessee | |
Vanderbilt University Medical Center | Recruiting |
Nashville, Tennessee, United States, 37209 | |
Contact: Jonathan D Casey, MD 615-322-3412 jonathan.d.casey@vanderbilt.edu | |
Contact: Matthew W Semler, MD, MSc 615-802-8428 matthew.w.semler@vanderbilt.edu | |
United States, Texas | |
Baylor Scott & White Medical Center - Temple | Recruiting |
Temple, Texas, United States, 76508 | |
Contact: Shekhar Ghamande, MD Shekhar.Ghamande@BSWHealth.org | |
United States, Washington | |
University of Washington | Recruiting |
Seattle, Washington, United States, 98195 | |
Contact: Aaron M Joffe, DO joffea@uw.edu |
Principal Investigator: | David R Janz, MD, MSCI | Louisiana State University Health Sciences Center in New Orleans | |
Principal Investigator: | Derek W Russell, MD | University of Alabama at Birmingham |
Responsible Party: | Matthew Semler, Assistant Professor of Medicine, Vanderbilt University Medical Center |
ClinicalTrials.gov Identifier: | NCT03787732 |
Other Study ID Numbers: |
IRB# 181690 |
First Posted: | December 26, 2018 Key Record Dates |
Last Update Posted: | December 2, 2020 |
Last Verified: | November 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Intubation |
Respiratory Insufficiency Hypotension Shock Respiration Disorders |
Respiratory Tract Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes |